Robert (Rulei) Chen
Senior Director, Global Strategy & Partnering, Genor Biopharma Co. Ltd.
Mr. Robert Chen is currently Senior Director, Head of Business DevelopmentatGenor Biopharma,a dedicated mAb product development and manufacturing company in China. His main responsibilities include business development, corporatestrategy, and intellectual propertymanagement.
He has more than 12 years of industrial experience in the biopharmaceutical industry.Prior to joining Wison, he worked for 2 years in a biopharmaceutical venture capital company, and developed his expertise in business development, company strategy and intellectual property management with two other biotechnology companies. Currentlythemost important part of his responsibilities is to help the company optimize its strategic positioning,andto establish strategic partnerships and future commercialization channels, both in China and globally. He has in-depth and unique understanding of how to effectively do strategic marketing and establish successful partnerships.
He finished his MS study of Neurobiology at the Chinese Academy of Sciences, and obtained his Bachelor of Biology from Wuhan University, both of which are among the top life science institutions in China. He also spent one year studying as a PhD candidate at the University of Florida, and completed a nearly one-year Executive Development Program (EDP) at Fudan University School of Management.
John Zhaolong Gong, PhD, MD
CEO, BL Pharmaceuticals
Dr. Gong joined BL Pharmaceuticals in March 2012. BL Pharma's mission is discover and develop innovative medicines to fulfill unmet medical needs through scientific research and collaborations with Chinese and western partners.
From 2008 to 2012, Dr. Gong served as CTO of JOINN Laboratories, he actively promoted and implemented international standards at JOINN, leading to the AAALAC accreditation in 2008, and US FDA inspection in 2009. Dr. Gong had ten years of US FDA regulatory experience in new drug development. He served as a Toxicology and Pharmacology Reviewer in the FDA's Center for Drug Evaluation and Research (CDER) and conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics.
Dr. Gong is a member of the Drug Safety Evaluation Committee of the Chinese Pharmaceutical Association, and an ad hoc specialist of AAALAC. He received his PhD in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.
H. Fai Poon, PhD
Director, Research & Development, Hisun Pharmaceutical
H. Fai Poon is currently R&D Director at Hisun Pharmaceutical. He previously worked at SAFC in which he collaborated with multiple biopharmaceutical companies (Samsung, Celltrion, Dong-A, Kaketsuken. Teva, Abbott, etc.) on their biologics manufacturing process improvement. Prior to SAFC, Dr. Poon worked at Roskamp Institute and lead their proteomic program. He has years of experience in the fields of industrial cell culture, bioanalytical research, bioinformatics and proteomics.
Dr. Poon completed his PhD in Biological Chemistry at the University of Kentucky, and his MBA at the University of South Florida. His MBA focus was on the application of lean management for laboratory efficiency improvement. He has published more than 30 peer-reviewed articles and authored three academic reviews, five book chapters and one book.
Dr. Poon is currently the associate editor for the Journal of Chemistry, Biochemistry and Molecular Biology, and associate editor-in chief for the International Journal of Bioinformatics and Biometrics. He has also served as a member of the editorial review board for the Scientific Journal International, the Society for Free Radical Biology and on the Medicine Young Investigator Awards (YIA) committee.